The European Union Approves Merck's Keytruda In Combination With Padcev As Neoadjuvant Treatment And Then Continued After Radical Cystectomy As Adjuvant Treatment, For Adults With Resectable Muscle-invasive Bladder Cancer Who Are Ineligible For Cisplatin-containing Chemotherapy

뉴스 본문을 불러오고 있어요.

The European Union Approves Merck's Keytruda In Combination With Padcev As Neoadjuvant Treatment And Then Continued After Radical Cystectomy As Adjuvant Treatment, For Adults With Resectable Muscle-invasive Bladder Cancer Who Are Ineligible For Cisplatin-containing Chemotherapy | 웨이프 WAPE

The European Union Approves Merck's Keytruda In Combination With Padcev As Neoadjuvant Treatment And Then Continued After Radical Cystectomy As Adjuvant Treatment, For Adults With Resectable Muscle-invasive Bladder Cancer Who Are Ineligible For Cisplatin-containing Chemotherapy

기사 요약

관련 종목

댓글 —